1: Shanahan MA, Salem A, Fisher A, Cho CS, Leverson G, Winslow ER, Weber SM.
Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors. J
Surg Res. 2016 Mar;201(1):38-43. doi: 10.1016/j.jss.2015.10.006. Epub 2015 Oct
11. PubMed PMID: 26850182.
2: Khan TM, Garg M, Warner RR, Uhr JH, Divino CM. Elevated Serum Pancreastatin Is
an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine
Tumors. Pancreas. 2016 Aug;45(7):1032-5. doi: 10.1097/MPA.0000000000000572.
PubMed PMID: 26684860.
3: Mir SA, Zhang K, Milic M, Gu Y, Rieg T, Ziegler M, Vaingankar SM. Analysis and
validation of traits associated with a single nucleotide polymorphism Gly364Ser
in catestatin using humanized chromogranin A mouse models. J Hypertens. 2016
Jan;34(1):68-78. doi: 10.1097/HJH.0000000000000760. PubMed PMID: 26556564.
4: Kaiserova M, Prikrylova Vranova H, Galuszka J, Stejskal D, Mensikova K,
Zapletalova J, Mares J, Kanovsky P. Orthostatic hypotension is associated with
decreased cerebrospinal fluid levels of chromogranin A in early stage of
Parkinson disease. Clin Auton Res. 2015 Oct;25(5):339-42. doi:
10.1007/s10286-015-0302-1. Epub 2015 Sep 10. PubMed PMID: 26359267.
5: Choi Y, Miura M, Nakata Y, Sugasawa T, Nissato S, Otsuki T, Sugawara J,
Iemitsu M, Kawakami Y, Shimano H, Iijima Y, Tanaka K, Kuno S, Allu PK, Mahapatra
NR, Maeda S, Takekoshi K. A common genetic variant of the chromogranin A-derived
peptide catestatin is associated with atherogenesis and hypertension in a
Japanese population. Endocr J. 2015;62(9):797-804. doi:
10.1507/endocrj.EJ14-0471. Epub 2015 Jul 25. PubMed PMID: 26211667.
6: Qi S, Huang M, Teng H, Lu Y, Jiang M, Wang L, Shi J, Ma Q, Gu G, Xin Y, Ma H.
Autoantibodies to chromogranin A are potential diagnostic biomarkers for
non-small cell lung cancer. Tumour Biol. 2015 Dec;36(12):9979-85. doi:
10.1007/s13277-015-3794-3. Epub 2015 Jul 18. PubMed PMID: 26186986.
7: Yang X, Yang Y, Li Z, Cheng C, Yang T, Wang C, Liu L, Liu S. Diagnostic value
of circulating chromogranin a for neuroendocrine tumors: a systematic review and
meta-analysis. PLoS One. 2015 Apr 20;10(4):e0124884. doi:
10.1371/journal.pone.0124884. eCollection 2015. Review. PubMed PMID: 25894842;
PubMed Central PMCID: PMC4403810.
8: Zhu D, Xie H, Wang X, Liang Y, Yu H, Gao W. Correlation of plasma catestatin
level and the prognosis of patients with acute myocardial infarction. PLoS One.
2015 Apr 7;10(4):e0122993. doi: 10.1371/journal.pone.0122993. eCollection 2015.
PubMed PMID: 25848973; PubMed Central PMCID: PMC4388679.
9: Wolf M, Riedlinger I, Lehmann R, Häring HU, Schleicher E, Peter A. Comparison
of the automated KRYPTOR chromogranin A assay with the DAKO ELISA. Clin Lab.
2014;60(12):2103-6. PubMed PMID: 25651748.
10: Brehm Hoej L, Parkner T, Soendersoe Knudsen C, Grønbaek H. A comparison of
three chromogranin A assays in patients with neuroendocrine tumours. J
Gastrointestin Liver Dis. 2014 Dec;23(4):419-24. doi:
10.15403/jgld.2014.1121.234.3ca. PubMed PMID: 25532001.
11: Wang YH, Yang QC, Lin Y, Xue L, Chen MH, Chen J. Chromogranin A as a marker
for diagnosis, treatment, and survival in patients with gastroenteropancreatic
neuroendocrine neoplasm. Medicine (Baltimore). 2014 Dec;93(27):e247. doi:
10.1097/MD.0000000000000247. PubMed PMID: 25501094; PubMed Central PMCID:
PMC4602794.
12: Chou WC, Chen JS, Hung YS, Hsu JT, Chen TC, Sun CF, Lu CH, Hwang TL. Plasma
chromogranin A levels predict survival and tumor response in patients with
advanced gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2014
Oct;34(10):5661-9. PubMed PMID: 25275071.
13: Hijioka M, Ito T, Igarashi H, Fujimori N, Lee L, Nakamura T, Jensen RT,
Takayanagi R. Serum chromogranin A is a useful marker for Japanese patients with
pancreatic neuroendocrine tumors. Cancer Sci. 2014 Nov;105(11):1464-71. doi:
10.1111/cas.12533. Epub 2014 Oct 18. PubMed PMID: 25220535; PubMed Central PMCID:
PMC4462381.
14: Mazzawi T, Gundersen D, Hausken T, El-Salhy M. Increased gastric chromogranin
A cell density following changes to diets of patients with irritable bowel
syndrome. Mol Med Rep. 2014 Nov;10(5):2322-6. doi: 10.3892/mmr.2014.2498. Epub
2014 Aug 18. PubMed PMID: 25174455; PubMed Central PMCID: PMC4214334.
15: Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z, Bai CM, Zhao DC, Zhang TP, Zhao YP,
Song YL, Wang YH, Chen J, Lu CM. Chromogranin A is a reliable serum diagnostic
biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC
Endocr Disord. 2014 Aug 7;14:64. doi: 10.1186/1472-6823-14-64. PubMed PMID:
25099181; PubMed Central PMCID: PMC4130880.
16: Dominguez N, Estevez-Herrera J, Borges R, Machado JD. The interaction between
chromogranin A and catecholamines governs exocytosis. FASEB J. 2014
Nov;28(11):4657-67. doi: 10.1096/fj.14-249607. Epub 2014 Jul 30. PubMed PMID:
25077558.
17: Burgio SL, Conteduca V, Menna C, Carretta E, Rossi L, Bianchi E, Kopf B,
Fabbri F, Amadori D, De Giorgi U. Chromogranin A predicts outcome in prostate
cancer patients treated with abiraterone. Endocr Relat Cancer. 2014 May
8;21(3):487-93. doi: 10.1530/ERC-14-0071. Print 2014 Jun. PubMed PMID: 24741024.
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Human Chromogranin A Partial [19-457] Recombinant Protein C- His Tag” Cancel reply
Related products
Biosimilar
Adalimumab Biosimilar – Anti-TNF alpha mAb – Research Grade
Reviews
There are no reviews yet.